Keymed Biosciences Announces 2025 Annual Results and Business Updates
PR Newswire —
BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. Total revenue in 2025 was approximately RMB 720 million, a 67% year-on-year increase. This included around RMB 310 million from sales of the core product Kangyueda® and...